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Abstract: Gangliosides stimulate the hydrolysis of glucosyl- 
ceramide (GlcCer), their precursor, and therefore may lower 
the level of cellular GlcCer and exert a feedback control effect 
to slow the formation of gangliosides. Tests were made to see 
if a similar effect on GlcCer levels can be exerted by the 
action of gangliosides on GlcCer synthesis. Using a new assay 
procedure, we showed that gangliosides do inhibit the synthase 
in brain membranes quite effectively, the most active being 
those lipids with more sugar and sialic acid moieties. Mice 
injected with a mixture of brain gangliosides for 5 days were 
found to have a lower level of ceramide:UDP-Glc glucosyl- 
transferase activity in brain, liver, and kidney. The inhibition 
seems to be exerted by competition for the active site and 
binding to effector site(s) on the enzyme. It is possible that 
the reported therapeutic actions of gangliosides on the nervous 
system are, in part, the result of lowered levels of GlcCer. 
Malignant tumors shed gangliosides into the extracellular 
fluid, which are believed to block the generation of antibodies 
by the host’s immunodefense system; this effect also may be 
due, in part, to reduction in the GlcCer level of immunogenic 
cells. A new finding is that a ceramide containing phyto- 
sphingosine is a markedly better substrate for GlcCer synthase 
than one containing the more common base. Key Words: 
Ganglioside-Glucosylceramide synthase-Modulation of 
glycolipid synthesis-Octanoyl phytosphingosine. Shukla 
G. S. et al. Gangliosides inhibit glucosylceramide synthase: 
A possible role in ganglioside therapy. J. Neurochem. 56, 
21 25-2132 (1991). 
Glucosylceramide (GlcCer) occupies an important 
branch control position in sphingolipid metabolism. It 
is the precursor of all the glucose-based sphingolipids 
(GSLs) and its precursor, ceramide, has only two other 
known anabolic roles, the syntheses of galactosylcer- 
amide and sphingomyelin. The proposal has been of- 
fered that the level of GlcCer in cells controls their rate 
of cell proliferation. One such relationship is seen in 
Gaucher patients, who accumulate GlcCer because of 
defective GlcCer hydrolysis; they exhibit greatly en- 
larged spleen, liver, and bone marrow. Injection of 
GlcCer emulsion into mice causes rapid growth of the 
liver (Datta and Radin, 1988). At low levels in cell 
media, sphingosine-which is rapidly converted to 
ceramide (Braun et al., 1970) and, presumably, to 
GlcCer-produces markedly faster cell proliferation 
(Zhang et al., 1990). When mice were given eight daily 
injections of conduritol B epoxide, which inactivates 
GlcCer glucosidase and causes accumulation of GlcCer, 
brain and liver became significantly enlarged (Hara and 
Radin, 1979). 
Conversely, reduction in GlcCer level by an inhibitor 
of GlcCer synthase (ceramide:UDP-Glc glucosyltrans- 
ferase, EC 2.4.1.80) results in the opposite effect, re- 
tardation of cell growth (Inokuchi et al., 1990; J. A. 
Shayman et al., submitted). It also blocks the prolif- 
erative effect of mitogens (Felding-Habermann et al., 
1990), the adhesion and migration of tumor cells 
(Inokuchi et al., 1990), and, in vivo, slows the growth 
of tumor cells (Inokuchi et al., 1987). 
Although the mechanism by which GlcCer exerts 
this growth effect is still unclear, it is well worth ex- 
amining the glucosyltransferase’s sensitivity to biolog- 
ical factors. Gangliosides are of particular interest be- 
cause they are products of GlcCer anabolism and might 
therefore exert some sort of feedback control over the 
anabolic process. Many therapeutic effects on the ner- 
vous system have been claimed to arise from ganglio- 
side injection and gangliosides have often been ob- 
served to  slow cell growth in vitro. It seemed likely 
from these observations that gangliosides act as negative 
modulators on GlcCer synthesis. 
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MATERIALS AND METHODS 
Gangliosides, long-chain ceramides produced enzymati- 
cally from bovine brain sphingomyelin, and most other re- 
agents were from Sigma Chemical. A mixture of gangliosides 
was prepared from brain by extraction with chloroform/ 
methanol, partitioning against water, and ion exchange. 
Short-chain ceramides (N-octanoyl sphingosine and N-oc- 
tanoyl phytosphingosine) were prepared from octanoyl chlo- 
ride and the corresponding sphingol (Vunnam and Radin, 
1979). UDP-~-[6-~H]glucose was from Amersham. 
GicCer synthase was assayed in duplicate or triplicate tubes 
by modifications ofan improved method (Vunnam and Ra- 
din, 1979; Shukla and Radin, 1990), using 150 pM UDP- 
Glc (80,000 cpm); 2 mM ATP 1 mM dithioerythritol (DTE); 
2 mM Na2EDTA; 10 mM MnClz; 0.1 A4 Tris-CI-, pH 7.4 
(at 37°C); and liposomal substrate, in a total volume of 0.2 
ml. The lipoidal dispersion consisted of 85 pg of octanoyl 
sphingosine, 565 pg of dioleoyl phosphatidylcholine, and 100 
pg of brain sulfatide. The radioactive cerebroside that was 
formed was separated from the precursor by a new parti- 
tioning solvent and counted by liquid scintillation. This 
method yielded a standard deviation of ~ 3 % .  Compounds 
tested for their action on the enzyme were evaporated to 
dryness from solution in the incubation tube, after which the 
enzyme-cocktail mixture was pipetted in and incubated for 
60 min in an ultrasonic bath maintained at 37°C. As enzyme 
source, in most cases, we used microsomes from brains of 
-4-month-old mice of the ICR strain, from Harlan Sprague 
Dawley. The microsomes were prepared by centrifuging a 
10% homogenate in 0.32 Msucrose at 755 gfor 10 min, then 
at 12,000 g for 20 min and at 135,000 g for 1 h. The pellets 
were resuspended in the original homogenate volume of su- 
crose and stored at -70°C in portions. Portions containing 
77,99, and 44 pg of protein from each fraction, respectively, 
were used for the subcellular comparison. 
Protein was determined by the bicinchoninic acid method 
(Smith et al., 1985) with bovine serum albumin as standard. 
The data were analyzed by one-way analysis of variance 
and differences between control and experimental values were 
considered significant if they reached the 295% confidence 
interval in the Scheffi F test. 
RESULTS 
A study with various gangliosides showed that they 
inhibited the enzyme and that the extent of the effect 
was smallest with the smallest ganglioside (Fig. 1). 
Asialo-GM1 was almost inert. At 20 pM, all three of 
the larger gangliosides had very similar inhibitory ef- 
fects (- 13%) but a striking divergence, then a new 
convergence appeared at higher concentrations (almost 
complete inhibition at 100 pM ganglioside). The dif- 
ferences between the individual curves could be as- 
cribed to different affinities for different sites on the 
enzyme or other microsomal components. The most 
effective was GDla, which was used for most of the 
other studies. The inhibitory effect was seen in kidney 
and liver microsomes as well as in brain. 
Tests with 25-100 pM concentrations of related 
compounds, sialic acid, GlcCer, lactosylceramide, 
sphingomyelin, sphingosine, and phytosphingosine 
showed them to be inert. Two poly-acids, yeast ribo- 
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FIG. 1. Effects of different gangliosides and their concentrations 
on the synthesis of GlcCer. Each tube contained 20 pg of protein 
in the microsornes (derived from 1.6 mg of brain) and the uninhibited 
basal activity was 388 pmol/h. The data points shown are derived 
from two experiments; each point is the mean value obtained from 
four incubation tubes. 
nucleic acid and chondroitin sulfate, which resemble 
gangliosides in their ionic charge, also proved to be 
inert at 25-100 pg/ml. 
Some ceramide glucosyltransferase is present in 
larger particulate fractions (Shukla and Radin, 1990) 
and it was of interest to see if the enzymes in the other 
membranes were similar in their sensitivity to ganglio- 
sides. The inhibitory effect was distinctly less in these 
particles: 17% and 29% at 60 pM GDla for the 755 g 
and 12,000 g particles, respectively, compared with 77% 
for microsomes. Although the difference could be at- 
tributed to qualitatively different glucosyltransferases, 
it seems more likely that it is due to differences in the 
amounts of ganglioside-binding protein or other ma- 
terial in the different preparations. Several such agents 
have been characterized (Thompson et al., 1986; Tie- 
meyer et al., 1989; Sonnino et al., 1989). 
This possibility was examined by incubating micro- 
somes with boiled microsomes, bovine serum albumin, 
or fetuin from fetal calf serum (6.8% sialic acid). In the 
absence of ganglioside, the proteins had no effect (Fig. 
2). Without added proteins, GD la produced marked 
inhibition. All three preparations, especially the boiled 
microsomes, reduced the effectiveness of the ganglio- 
side. This finding supports the above interpretation. 
Serum albumin, of course, is known for its ability to 
bind a wide variety of lipids, including gangliosides 
(Venerando et al., 1982). The ability of albumin to 
reverse the inhibitory effect of ganglioside indicates that 
the binding constant for the complexing of GD 1 a and 
enzyme is not much lower than that for albumin and 
GD 1 a. 
The binding material appears to be present also in 
undenatured microsomes, as shown by evaluating the 
effect of changing the weight of intact microsomes in 
the incubation tubes (Fig. 3). In the absence of GDla, 
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FIG. 2. Effect of proteins on inhibition of microsomal GlcCer syn- 
thase by 50 pM GD1 a. Conditions as in Fig. 1. Each symbol shows 
the value from one assay tube: many of the duplicate points are 
too close to distinguish as separate symbols. BM, boiled micro- 
somes; FTN, fetuin. 
the observed enzyme activity was proportional to the 
weight of microsomes. When GDla was included, its 
inhibitory effect was strongest at the low levels of mi- 
crosomes, evidently because of the low amount of gan- 
glioside-binding material in these tubes. Above 50 pg 
of microsomal protein, the ganglioside had only a small 
effect. 
The degree of inhibition by GD 1 a was independent 
of time over a 2-h period and the effect appeared even 
at the first time point studied, 15 min. Thus the gan- 
glioside does not act by destabilizing the enzyme. 
In the absence of substrates, the transferase is un- 
stable at 37°C. In the absence ofganglioside, a 10-min 
preincubation with C8 ceramide and nonradioactive 
UDP-Glc (bottom line of Table l), followed by addition 
1000 fl
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FIG. 3. Relationship between microsome weight and the inhibitory 
effect of G D l a  on GlcCer synthase. Each symbol shows the value 
from one assay tube: many of the duplicate points are too close 
to distinguish as separate symbols. 
TABLE 1. Effect of preincubating mouse brain 
microsomesfor 10 min on the inhibitory effect of50 gM 
ganglioside GDla added prior to preincubating 
Preincubation conditions Without GDla With GDla 
~ ~ 
UDP-Glc 328 _t 5 78 f 2 
Ceramide (octanoyl sphingosine) 363 f 5 98 f 2 
No substrates 304 f 5 55 * 2 
Both substrates 382 k 5 111 * 2  
Data are picomoles of GlcCer formed f SD after triplicate 60-min 
incubations with 20 pg of microsomal protein. 
of undiluted [3H]UDP-Glc and incubation for 1 h, 
yielded almost the same amount of GlcCer as non- 
preincubated tubes. If both substrates were omitted 
during the preincubation, there was a 20% loss in ac- 
tivity. Omitting either one of the substrates caused a 
smaller loss, indicating that both compounds stabilized 
the enzyme. 
When ganglioside was included in preincubation 
medium with both substrates, there was 7 1 % inhibition. 
When both substrates were omitted during the prein- 
cubation, the ganglioside was even more effective- 
82% inhibition. Thus the ganglioside may compete with 
both substrates for sites on the enzyme. Not shown in 
the table is the inhibition seen when the partially in- 
activated enzyme was exposed to ganglioside after the 
preincubation period; here the inhibition was only 55%. 
It is possible that the partially denatured enzyme has 
a lower affinity for the inhibitor. 
When the preincubations were carried out at O'C, 
there was almost no loss of enzyme activity or any 
effect on the magnitude of the inhibitory effect of gan- 
glioside. When 50 ph4GDla was preincubated at 37°C 
for 10 min with microsomes and nonradioactive cock- 
tail in a small volume, then diluted up to four times 
with radioactive cocktail and incubated for 60 min, 
the amount of inhibition was substantially the same 
in all tubes (data not shown). This suggests that the 
enzyme bound fairly strongly to the ganglioside; the 
complex did not dissociate due to dilution. 
To test this hypothesis further, we preincubated brain 
and liver microsomes with 50 pM GDla for 10 min 
at 37"C, then diluted the suspension 10 times with 
water and centrifuged it for 60 min at 100,000 g to 
recover the particles. When the particles (40 pg of pro- 
tein) were incubated in the standard assay system in 
triplicate for 30 min with the ceramide liposomes, the 
ganglioside-treated particles were found to exhibit lower 
activities. With brain, the control microsomes synthe- 
sized 350 f 1 nmol of GlcCer; the pretreated particles 
synthesized 195 rfr 0.8 nmol of GlcCer. From this it 
would appear that the particles had absorbed enough 
ganglioside to inhibit the synthase by 56%, despite the 
washing step. With liver, the corresponding figures were 
107 -t 0.5 and 63 t- 0.3, for an inhibition of 41%. 
Another set of tubes was incubated without ceramide 
liposomes, to see if ganglioside inhibited the synthesis 
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of GlcCer when the endogenous ceramides acted as 
glucose acceptor. The synthesis of GlcCer from the en- 
dogenous ceramides was zero for brain (indicating un- 
availability or absence of microsomal ceramides). With 
liver membranes the incubation yielded 30 +- 0.2 nmol 
of GlcCer for the controls and 22 * 0.2 nmol for the 
GD 1 a-treated membranes, for an inhibition of 27%. 
Thus the inhibitory action of gangliosides on GlcCer 
synthase is not an artefact due to using the more re- 
active octanoyl sphingosine or a liposomal substrate. 
Because gangliosides form complexes with divalent 
metallic cations, of varying degrees of association, it 
was of interest to determine whether cations influence 
the inhibitory effect (Table 2). With different Mn2+ 
concentrations, the basal system showed maximal en- 
zyme activity at 10 mM (the concentration used in all 
other experiments). Inhibition by GDla was seen at 
all concentrations of Mn2+, so it appears that a cation 
is not involved in formation of the enzyme-ganghoside 
complex. In the case of Mg2+ and Ca2+, the basal system 
was most highly activated at 15 mM. The effectiveness 
of Ca2+ is a new finding for brain microsomal gluco- 
syltransferase; however, we did find similar stimulation 
by Ca2+ in whole kidney homogenates (Shukla and 
Radin, 1990). The inhibitory effect of ganglioside was 
reduced by high concentrations of all three cations, 
particularly Ca2+. This effect was probably due to com- 
petitive complexing of the ganglioside by cations in- 
stead of by enzyme. 
When the basal enzyme cocktail was modified by 
omitting single components (EDTA, DTE, and ATP), 
the inhibitory effect of GDla was not much different. 
However, the inhibition was consistently a little smaller 
in the absence of ATP. Similar inhibition was produced 
TABLE 2. Effect of differing cation concentrations 
on the inhibitory activity of ganglioside GDla 
[Cation] 
(mM) GDla Mn2+ MgZ+ Ca2+ 
0 - 225 223 227 
+ 116 -29% 156 -30% 161 -29% 
2.5 - 242 238 239 
t 165 -32% 169 -29% 170 -29% 
5 - 302 277 284 
+ 211 -30% 202 -27% 219 -23% 
10 - 388 331 327 
+ 283 -27% 248 -25% 271 -17% 
15 - 316 342 339 
20 - 249 32 1 336 
+ 240 -24% 263 -23% 250 -13% 
+ 207 -17% 289 -10% 306 -9% 
The standard incubation conditions were used, with 20 p g  of mi- 
crosomal protein and without the usual Mnz+. A minus sign indicates 
no ganglioside was present; a plus sign indicates the presence of 25 
p M  GD la. The activities shown are the means of duplicate assays, 
in picomoles per hour of GlcCer formed. 
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FIG. 4. Effects of two inhibitors, ganglioside GDla and PDMP, on 
the synthesis of GlcCer by 37.5 fig of rnicrosomal protein, incubated 
as described in the legend to Fig. 1. The error bars indicate the 
SD values obtained from three incubation tubes. 
by GDla when the octanoyl sphingosine was replaced 
with other ceramides (octanoyl phytosphingosine and 
long-chain mixed ceramides). 
D-th WO- 1 -Phenyl-2-decanoylamino-3-morpholino- 
1-propanol (PDMP), a cationic ceramide analog, is a 
stronger inhibitor of ceramide glucosyltransferase, act- 
ing as an uncompetitive inhibitor against UDP-Glc and 
a mixed-type competitor against ceramide (Inokuchi 
and Radin, 1987). This suggests that the cationic lipid 
binds to the ceramide-binding catalytic site as well as 
a more distant site. Because gangliosides contain a cer- 
amide moiety, it seemed possible that both inhibitors 
bind to a similar region in the catalytic site and another 
similar region in an effector site. When the two inhib- 
itors were compared separately and together (see bars 
3-6, Fig. 4), the extra inhibition produced by adding 
ganglioside to the PDMP-containing tubes was inde- 
pendent of the PDMP concentration. Thus it would 
appear that the two inhibitors act, in part, at different 
sites on the enzyme. 
When we examined two common acidic lipids, 
phosphatidylserine and oleic acid, we found that they 
were rather weak inhibitors of glucosyltransferase (Fig. 
5 ) .  Phosphatidylserine partially blocked the inhibitory 
action of GDla (bar 4 versus bar 2) and, in combi- 
nation with oleic acid (bar 8 versus bar 7), it prevented 
the inhibition completely. This may indicate that the 
acidic lipids compete for the same sites on the enzyme 
molecule. However, another possibility is that the acidic 
lipids formed a complex with the ganglioside and Mn2+, 
preventing GDla uptake by the membrane. 
A kinetic analysis of the effect of GD 1 a with regard 
to UDP-Glc (Fig. 6) showed that the ganglioside acts 
as a mixed type inhibitor, possibly at the active site 
and at some other site. The K,,, and V,,, values for the 
uninhibited enzyme were 35 pLM and 21 pmol/h/mg 
of protein, respectively. For the inhibited enzyme (25 
pLM GDla) these values were 44 and 16, respectively. 
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FIG. 5. Interaction between ganglioside, phosphatidylserine (PS, 
0.25 mM), and oleic acid (OA, 0.75 mM), with respect to the activity 
of microsomal (44 pg of protein) glucosyltransferase. The error 
bars indicate the SD values obtained from three incubation tubes. 
With regard to octanoyl sphingosine, the K, and 
V,,, values for the uninhibited enzyme were 30 pM 
and 18.5 pmol/h/mg of protein, respectively (Fig. 7). 
The ganglioside did not change the K, for ceramide 
but did lower the V,,, by 31%, so apparently it acts 
against the ceramide as a noncompetitive inhibitor by 
binding to the enzyme at a noncatalytic site that slows 
the enzyme. From these two evaluations, it seems likely 
that the ceramide moiety of gangliosides binds to the 
same effector site as the lipoidal substrate and the 
sialooligosaccharide moiety binds to a region close to 
the catalytic site, in competition with the nucleotide 
sugar. 
When octanoyl phytosphingosine was used as the 
lipoidal substrate, it was found to be a markedly better 
substrate than the nonhydroxy compound with brain, 
liver, and kidney microsomes. With brain, the K, and 
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FIG. 6. Lineweaver-Burk plot relating GlcCer synthesis by micro- 
somes (20 pg of protein) to UDP-Glc concentration. Each symbol 
shows the value from one assay tube; many of the duplicate points 
are too close to distinguish as separate symbols. 
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FIG. 7. Lineweaver-Burk plot relating GIcCer synthesis to con- 
centration of N-octanoyl sphingosine. Each symbol shows the value 
from one assay tube; many of the duplicate points are too close 
to distinguish as separate symbols. 
and 32 pmol/h/mg of protein. Here too the ganglioside 
resulted in noncompetitive inhibition. It is interesting 
that phytosphingosine GSLs occur primarily in kidney 
and intestine of mammals, not in brain. Perhaps the 
lack of this sphingol in brain GSLs is due to lack of 
the base rather than to lack of enzymes for utilizing it. 
The mechanism of inhibitory action by gangliosides 
apparently involves binding of the acidic lipid to the 
enzyme, because we have shown that GDla  acts as a 
mixed type inhibitor toward the nonlipid substrate, 
UDP-Glc. The possibility that they act by affecting the 
liposomal structure of the substrate is low because, as 
noted above, we found that GDla  is inhibitory even 
when endogenous ceramides (containing long-chain 
fatty acids) act as glucose acceptor. It is unlikely that 
gangliosides, which are carboxylic acids, can act as de- 
tergents and affect liposomes in our incubation media, 
which contain a high level of divalent cations. Oleic 
acid, which is a good detergent in the Na’ form, is also 
inactive as a detergent in our media and was a weak 
inhibitor in our system (Fig. 5). Even a commercial 
high-efficiency detergent, such as Triton X- 100, has 
little detergency power at concentrations below 500 
pg/ml; in our system, gangliosides at - 100 pg/ml were 
effective inhibitors. It may be noted that cerebroside 
sulfate, which might have some detergent properties 
even in a Mn’+-containing medium, is a component 
of our ceramide liposomes and is a modest stimulator 
in our assay system. Omission of the sulfatide from 
the substrate liposomes did not affect the degree of in- 
hibition by ganglioside. 
The competition for ganglioside molecules between 
GlcCer synthase and other ganglioside-binding sub- 
stances may explain several phenomena. For example, 
the B subunit of cholera toxin binds strongly to gan- 
glioside GM1 in rat thymocytes and its exogenous ad- 
dition to the cells could be expected to relieve the nor- 
mal inhibitory effect of GM 1 on GlcCer synthesis. The 
J Neurochem., Vol. 56. No. 6 ,  1991 
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resultant increase in GlcCer might then induce the cell 
proliferation that was observed experimentally (Spiegel 
et al., 1985). A partial test of this idea was camed out 
by testing the ability of cholera toxin B subunit to block 
the inhibitory effect of ganglioside GMl (Fig. 8). The 
toxin preparation itself had some inhibitory effect on 
the glucosyltransferase, possibly due to the NaCl in the 
Sigma preparation (no. C-777 1, from Vibrio cholerae). 
It was apparent that it blocked the inhibition by GM 1 
in a dose-related manner. Evidently the toxin has a 
higher affinity than GlcCer synthase for GM 1. Varia- 
tions in the concentrations of the various natural gan- 
glioside-binding tissue components may act to control 
GlcCer synthesis. 
Because gangliosides have been found to produce 
therapeutic effects in vivo, but by an unknown mech- 
anism, we tested their effect on GlcCer synthase after 
injection. Groups of six mice each (35-37 g) were in- 
jected intraperitoneally daily for 5 days with 50 mg/ 
kg of mixed brain gangliosides in saline, and killed 3 
h after the last injection. [This dosage level had been 
used by Sparrow and Grafstein ( 1982) and Gorio et al. 
(1980).] Homogenates of brain, liver, and kidney were 
assayed for GlcCer synthase (Table 3). In the case of 
kidney, NAD was included in the assay tubes (Shukla 
and Radin, 1990). Significantly lower levels of enzyme 
activity were observed, especially with liver. 
DISCUSSION 
Our finding that GlcCer synthesis can be slowed by 
gangliosides raises the question of therapeutic and 
physiological relevance of the finding: do cellular gan- 
gliosides, exogenous or endogenous, actually modulate 
the level of GlcCer and (indirectly) the levels of the 
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FIG. 8. Inhibition of GlcCer by ganglioside GM1 and reversal of 
the effect by cholera toxin B (CTB) subunit. The toxin solution 
contained 500 pg of protein (35 toxoid unitslpg) in 50 mM Tris, 
pH 7.5; 200 mM NaCI; 3 rnM NaN,; and 1 mM Na2EDTA. Each 
tube, except the controls, contained 50 p M  GMl and various 
amounts of toxin solution. Triplicate tubes were incubated for 60 
min and the means and SD values are shown. 




Organ analyzed Control mice mice Percent inhibition 
Brain 554 rt 22 495 f 25 1 1  
Liver 370 f 31 270 2 14 27 
Kidney 680 k 26 619 2 23 9 
Each value is the activity of the enzyme, in pmol/30 min/3 mg 
tissue rt SD. Control mice received saline and experimental mice 
received 50 mg/kg of brain gangliosides in saline intraperitoneally 
daily for 5 days. All three decreases are significant. p < 0.000 I .  
sensitivity versus ganglioside concentrations found in 
tissues. In human brain gray matter, the concentration 
of total gangliosides was found to be - 1,000 nmol/g 
(Kishimoto and Radin, 1965), which is roughly 20 
times the concentration needed to produce strong in- 
hibition in our microsomal assay. This comparison is 
not simple because most of the ganglioside in tissues 
is surely already bound to specific proteins, including, 
perhaps, GlcCer synthase. Nevertheless, the contrast 
in concentrations suggests that a small release or ex- 
ogenous addition of gangliosides could act physiolog- 
ically as a negative modulator of GSL synthesis. The 
above proposed normal role for ganglioside is consis- 
tent with the observation that the measured activity of 
GlcCer synthase in brain drops off sharply as the gan- 
glioside concentration approaches a maximum and cell 
proliferation slows (Brenkert and Radin, 1972). 
Such an effect could also occur in neurologically 
damaged patients and in animals that are injected with 
gangliosides [see reviews by Ledeen (1 987) and Ma- 
hadik and Karpiak (1988)]. In this type of therapy, 
large amounts of ganglioside are injected for many days 
and it might thus be possible to attribute the beneficial 
actions of the lipids to a slowing in GlcCer synthesis. 
The resulting decrease in GlcCer level might slow any 
undesirable cell proliferation that may occur after brain 
damage. In support of this hypothesis are articles 
showing that exogenous gangliosides inhibit cell growth 
(Bremer et al., 1984; Sobue et al., 1988) as well as the 
articles that link GlcCer levels to cell growth rates (see 
introductory section). Several enzymes have been 
found to be modulated as the result of injecting gan- 
gliosides into animals (cited by Mahadik and Karpiak, 
1988). 
Further supporting our hypothesis that gangliosides 
can actually inhibit GlcCer synthase in vivo is our 
finding that gangliosides injected at a therapeutic level 
produced a distinct lowering in the glucosyltransferase 
activity in the three organs studied (Table 3). We in- 
terpret this to mean that the tissues retained enough 
of the injected lipid to reduce the GlcCer synthase even 
when diluted for the assay procedure. It is possible that 
some of the observed decrease in activity was due to a 
more complex effect, such as a reduction in the level 
of mRNA responsible for synthesizing the enzyme. 
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However, inhibitors usually produce an increased level 
of enzyme synthesis through a feedback relationship. 
There is evidence that malignant tumors shed or 
excrete relatively large amounts of ganglioside (Schulz 
et al., 1984; Ladisch et al., 1987; Bergelson et al., 1989). 
It has been proposed that these lipids are responsible 
for the disappointing adequacy of the patient’s immune 
system response to tumor antigens. With certain tu- 
mors there is enough shed GSL to make the tumor’s 
presence detectable in the blood, so that a diagnostic 
or prognostic test is feasible. Such secretion may sat- 
urate the body’s-and particularly the immunogenic 
cells’-normally binding ganglioside sites and thus lead 
to inhibition of the cells’ GlcCer synthase. Because the 
evidence cited above ties GlcCer levels to proliferation 
rates, this could explain why the immunorejection sys- 
tem in patients fails to reject tumor antigens and why 
cancer patients lose weight. T cells that were depleted 
of GlcCer and other GSLs by treatment with the syn- 
thase inhibitor PDMP failed to proliferate when ex- 
posed to mitogens (Felding-Habermann et al., 1990). 
Mice treated with PDMP lost weight quickly (Inokuchi 
et al., 1987). 
Additional support for this hypothesis comes from 
reports that gangliosides suppressed murine and human 
lymphocyte proliferation and interleukin 1 production 
in vitro (Whisler and Yates, 1980; Jeng et al., 1988). 
The plasma gangliosides from mice bearing the Ehrlich 
ascites tumor were found to enhance the growth of the 
tumor cells when the cells were inoculated into new 
animals together with the gangliosides (Saha and 
Ghosh, 1990). This effect could be due to blockage of 
the host’s immunogenic system. The level of ganglio- 
side-linked sialic acid in several cases of cancer patients 
was found to be -33 pM, high enough perhaps to 
inhibit GlcCer synthase in the patient’s body (Kloppel 
et al., 1977). In addition, it is possible that tumor cells 
have an unusual ability to shed themselves of ganglio- 
sides (due to lack of binding proteins) and can therefore 
relieve their own GlcCer synthase from the normal 
amount of inhibition; this could enhance tumor cell 
proliferation. 
Our postulated role for gangliosides in controlling 
GlcCer levels is given strong support by the previous 
demonstration that these GSLs also stimulate GlcCer 
glucosidase (Mueller and Rosenberg, 1979; Sarmientos 
et al., 1986). This effect would augment the inhibitory 
action on the synthase, helping to lower cellular GlcCer 
levels even further. Supporting this conclusion are the 
findings that gangliosides of different structures pro- 
duced parallel effects on the two enzymes (Fig. 1). These 
dual GlcCer lowering effects of gangliosides could ex- 
plain the observation that exogenous gangliosides 
stimulate the breakdown of phosphoinositides by a 
mechanism that does not involve the stimulation of 
neurite outgrowth (Vaswani et al., 1990). We have re- 
cently shown that depletion of kidney cell GlcCer by 
PDMP enhances the cells’ ability to respond to stim- 
ulation by bradykinin, which normally activates the 
hydrolysis of phosphatidylinositol diphosphate (Shay- 
man et al., 1990). Thus, a lack of GlcCer, produced 
by PDMP or by ganglioside, enhances the hydrolysis 
of inositol lipid. 
Our postulated modulating roles of gangliosides de- 
scribed above should not be construed as implying that 
the known specific binding and enzyme-activating 
properties of gangliosides have no function or that the 
many observations made with GSLs can be explained 
via only one property. Ganglioside effects that take 
some time to become evident are more likely to be due 
to the GlcCer-lowering mechanism. 
A study of GM3:UDP-N-acetylgalactosamine ami- 
nosugar transferase in microsomes from chicken retina 
(Nores and Caputto, 1984) revealed that this enzyme 
resembles glucosyltransferase with regard to its inter- 
actions with gangliosides. As in our system, gangliosides 
were found to inhibit strongly (but at higher ganglioside 
concentrations), to bind to the microsomes, and to in- 
hibit more effectively at lower microsome concentra- 
tions than at higher concentrations. An earlier study 
of this enzyme, using Tay-Sachs brain, also reported 
the inhibitory effect of gangliosides (Yu et al., 1983). 
The assay system included Triton X- 100, so it is clear 
that the presence of a detergent did not block the effect 
of the sialolipids. An important conclusion from this 
study, very relevant to our conclusions, is that the 
known accumulation of GM3 and GD3 in Tay-Sachs 
brain is due to the inhibitory action of the accumulated 
galactosaminyl gangliosides in these patients. 
Another enzyme in the GSL series, GM3 synthase 
of rat liver Golgi apparatus, was also found to be in- 
hibited by various gangliosides, but at very high con- 
centrations (Richardson et al., 1977). 
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